DEF: Beauty Health Company Outlines Director Nominees, Executive Compensation, and Governance Practices in Proxy Statement

The Beauty Health Company's proxy statement details director nominees, executive compensation, corporate governance, and upcoming annual meeting information for stockholders.

Summary

• The Beauty Health Company has released its proxy statement for the annual meeting of stockholders to be held on June 12, 2025.
• The proxy statement includes proposals for the election of seven directors, ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm, and an advisory vote to approve named executive officer compensation.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of Deloitte, and FOR the named executive officer compensation.
• The annual meeting will be held virtually at www.virtualshareholdermeeting.com/SKIN2025.
• The record date for determining stockholders eligible to vote at the annual meeting was April 16, 2025.
• The proxy statement also details the compensation of directors and executive officers, including base salaries, bonuses, stock awards, and other benefits.
• The company's corporate governance practices, including board committees and their responsibilities, are also outlined.
• The proxy statement also discusses certain legal proceedings involving the company and its officers and directors.
• The company's commitment to environmental, social, and governance (ESG) matters is highlighted, including initiatives related to recycling, data privacy, human rights, and business ethics.
• The company employed 769 employees as of December 31, 2024, with 60% based in the United States.
• The company's insider trading policy prohibits employees, officers, and directors from acquiring, selling, or trading in any interest or position relating to the future price of company securities, such as a put option, a call option or a short sale, or engage in hedging transactions.
• The company's insider trading policy prohibits employees, officers, and directors from pledging Company securities as collateral to secure loans.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative information. While it highlights the company's commitment to good governance and ESG matters, it also discusses ongoing legal proceedings and the failure to meet certain performance targets. The sentiment is neutral overall.

Positives

• The company has strong corporate governance practices, including an independent board and active committees.
• The company is committed to ESG matters, demonstrating a focus on sustainability and social responsibility.
• The company has a clawback policy in place to recover incentive-based compensation in certain circumstances.
• The company's stock ownership guidelines align the interests of executives and directors with those of stockholders.
• The company offers a comprehensive compensation package to attract and retain talented executives.
• The company has a diverse workforce, with a focus on inclusion and equal opportunity.

Negatives

• The company is involved in a securities class action and a consolidated derivative action, which could result in financial losses.
• The company's annual performance-based cash incentive plan for 2024 resulted in a total achievement percentage of only 7.05% due to not meeting revenue and adjusted EBITDA targets.
• The company's relative TSR was less than the 20th percentile, resulting in no shares earned.

Risks

• The ongoing securities class action and consolidated derivative action could result in significant financial losses and reputational damage.
• Failure to achieve performance targets could negatively impact executive compensation and stockholder value.
• Changes in economic conditions or industry trends could affect the company's ability to attract and retain talent.
• Cybersecurity threats and data breaches could compromise sensitive information and disrupt business operations.
• Regulatory changes and compliance requirements could increase operating costs and complexity.

Future Outlook

The company expects to completely terminate the Deferred Compensation Plan by the end of 2025.

Management Comments

• We are committed to good governance practices.
• Our governance practices seek to ensure that we conduct our affairs in a manner that matches the high standards we have set for our people, products, and services.
• We believe that good governance builds integrity and trust, strengthens the accountability of our Board, management and employees, promotes the long-term interests of our stockholders, and allows us to be a good corporate citizen in each of the countries where we do business.

Industry Context

The document provides insights into the compensation and governance practices of a company in the beauty health industry, allowing for comparison against industry peers and benchmarks.

Comparison to Industry Standards

• The document references a peer group of companies used for compensation benchmarking, including Axonics, Inc., Beyond Meat, Inc, Cutera, Inc, e.l.f. Beauty, Inc., Establishment Labs, European Wax Center, Evolus, Hims & Hers Health, InMode, Inspire Medical Systems, Interparfums, Inc., iRhythm Technologies, Inc., OneSpaWorld, Revance Therapeutics, Inc., Sonos Inc., Thorne HealthTech, Inc., and YETI Holdings, Inc.
• The document also references the Dow Jones US Select Medical Equipment Index as a benchmark for performance-based restricted stock units.
• The document mentions that the company targets base pay and variable short and long-term compensation at the market median level to attract the very best talent necessary for our continued success.

Legal Proceedings

• A securities class action was filed against the company and certain officers in November 2023, alleging materially misleading statements and/or omissions relating to Hydrafacials business, operations, and prospects, specifically with respect to the performance of and demand for the Syndeo 1.0 and 2.0 devices.
• A consolidated derivative action was filed in the Delaware Court of Chancery against certain officers and directors, alleging breach of fiduciary duty based on the alleged disclosure of knowingly false information and/or the alleged failure to respond to red flags relating to Hydrafacials business, operations, and prospects, specifically with respect to the performance of and demand for the Syndeo 1.0 and 2.0 devices.

Related Party Transactions

• The company has entered into indemnity agreements with each of its directors and executive officers.
• The company is party to an Investor Rights Agreement with LCP Edge Holdco, LLC, which gives LCP Edge Holdco the right to designate a number of directors for appointment or election to the Companys Board of Directors.

Stakeholder Impact

• The outcome of the securities class action and consolidated derivative action could impact shareholders.
• Executive compensation decisions could impact employee morale and retention.
• The company's ESG initiatives could impact its reputation and relationships with customers, suppliers, and other stakeholders.
• The election of directors will determine the leadership and direction of the company.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting of stockholders on June 12, 2025.
• The company will continue to defend itself in the ongoing securities class action and consolidated derivative action.
• The company will implement its compensation and governance practices as outlined in the proxy statement.

Key Dates

Keywords

executive compensation, board of directors, corporate governance, annual meeting, proxy statement, stockholders, Deloitte, ESG, equity compensation, financial performance, risk management, cybersecurity, legal proceedings, related party transactions, human capital, sustainability, incentive compensation, stock ownership, talent attraction, diversity, inclusion, compensation, directors, officers, employees, shares, stock, vote, meeting, company